Fig. 7

Changes of the PI3K-AKT-mTOR pathway, cytoskeletal architecture, and EMT-related indicators after the administration of the PI3K inhibitor wortmannin(Wort). (A) Protein expression associated with the PI3K-AKT-mTOR pathway after treatment with BPS and PI3K inhibitor. Data are showed as mean ± SD, and all experiments were repeated at least three times. **p < 0.01, ***p < 0.001 and ****p < 0.0001 compared with control group. #p < 0.05 and ##p < 0.01 compared to the 200 µM BPS group. (B) Immunofluorescence detection of cytoskeletal architecture changes after BPS and PI3K inhibitor treatment. Scale bar, 50 μm. (C) Expression of EMT-related proteins after BPS and PI3K inhibitor treatment.*p < 0.05 and ***p < 0.001 compared with control group. #p < 0.05 and ##p < 0.01 compared to the 200 µM BPS group. (D) Immunofluorescence images of EMT-related indicators in HK-2 cells after BPS and PI3K inhibitor treatment. Scale bar, 50 μm. Data are showed as mean ± SD, and all experiments were repeated three times.